The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Open accessAbstract
Background: Multiple sclerosis is an acquired demyelinating disease of the central nervous system. It is the second most common cause of disability in adults in United States after head trauma. Discussion: The etiology of MS is probably multifactorial, related to genetic, environmental, and several other factors. The pathogenesis is not fully understood but is believed to involve T‐cell‐mediated inflammation directed against myelin and other related proteins with a possible role for B cells. The McDonald criteria have been proposed and revised over the years to guide the diagnosis of MS and are based on clinical presentation and magnetic resonance imaging (MRI) of the brain and spinal cord to establish dissemination in time and space. The treatment of MS includes disease modification with immunomodulator drugs and symptom management to address the specific symptoms such as fatigue, spasticity, and pain. Conclusion: An update on etiology, pathogenesis, diagnosis, and immunomodulatory treatment of MS is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Cited by
Impact of Metabolic Syndrome on Neuroinflammation and the Blood–Brain Barrier
Van Dyken, P., & Lacoste, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00930 · Cited by 359
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Melatonin as an anti-inflammatory agent modulating inflammasome activation
Favero, G., Franceschetti, L., Bonomini, F., Rodella, L. F., & Rezzani, R. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1835195 · Cited by 233
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Broos, J. Y., van der Burgt, R. T. M., Konings, J., Rijnsburger, M., Werz, O., de Vries, H. E., Giera, M., & Kooij, G. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02981-w · Cited by 41
Metadata
- Authors
- Garg, N., & Smith, T. W.
- Venue
- Brain and Behavior
- Publisher
- Wiley
- Published
- 2015-08-03
- Volume
- 5
- Issue
- 9
- Pages
- e00362-e00362
- ISSN
- 2157-9032 (ISSN-L)
- 2162-3279
- OpenAlex
- W1825094415
- Cited by
- 348
- References
- 111
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. https://app.cochat.ai/papers/10.1002/brb3.362
- The paper
- Garg, N., & Smith, T. W. (2015). An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain and Behavior. https://doi.org/10.1002/brb3.362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.